Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Karpati

Showing results (11-20 of 213) with videos related to

Pageof 22
Sort By:
Neuromuscular Disorders : NMD|July 1, 1997
The scope of gene therapy in humans: scientific, safety and ethical considerationsG Karpati, H Lochmüller
Medicina Clinica|June 24, 1989
[Myositis with inclusion bodies]S Carpenter, G Karpati
Experimental Neurology|March 1, 1986
Skeletal muscle endurance: the effect of increased availability of endogenous long-chain fatty acid fuelM Soza, G Karpati
Human Pathology|July 1, 1986
Lysosomal storage in human skeletal muscleS Carpenter, G Karpati
Neurology|December 1, 1981
Sweat gland duct cells in Lafora disease: diagnosis by skin biopsyS Carpenter, G Karpati
Annals of Neurology|July 1, 1981
Ultrastructural findings in Lafora diseaseS Carpenter, G Karpati
Muscle & Nerve|November 1, 1993
The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseasesG Karpati, G Acsadi
The New England Journal of Medicine|March 2, 1995
Dystrophin, utrophin, and muscular dystrophyG Karpati, P Holland
American Journal of Medical Genetics|December 1, 1986
Small-caliber skeletal muscle fibers do not suffer deleterious consequences of dystrophic gene expressionG Karpati, S Carpenter
Brain : a Journal of Neurology|March 1, 1979
Duchenne muscular dystrophy: plasma membrane loss initiates muscle cell necrosis unless it is repairedS Carpenter, G Karpati
Pageof 22

Showing results (11-20 of 213) with videos related to

Sort By:
Pageof 22
Neuromuscular Disorders : NMD|July 1, 1997
The scope of gene therapy in humans: scientific, safety and ethical considerationsG Karpati, H Lochmüller
Medicina Clinica|June 24, 1989
[Myositis with inclusion bodies]S Carpenter, G Karpati
Experimental Neurology|March 1, 1986
Skeletal muscle endurance: the effect of increased availability of endogenous long-chain fatty acid fuelM Soza, G Karpati
Human Pathology|July 1, 1986
Lysosomal storage in human skeletal muscleS Carpenter, G Karpati
Neurology|December 1, 1981
Sweat gland duct cells in Lafora disease: diagnosis by skin biopsyS Carpenter, G Karpati
Annals of Neurology|July 1, 1981
Ultrastructural findings in Lafora diseaseS Carpenter, G Karpati
Muscle & Nerve|November 1, 1993
The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseasesG Karpati, G Acsadi
The New England Journal of Medicine|March 2, 1995
Dystrophin, utrophin, and muscular dystrophyG Karpati, P Holland
American Journal of Medical Genetics|December 1, 1986
Small-caliber skeletal muscle fibers do not suffer deleterious consequences of dystrophic gene expressionG Karpati, S Carpenter
Brain : a Journal of Neurology|March 1, 1979
Duchenne muscular dystrophy: plasma membrane loss initiates muscle cell necrosis unless it is repairedS Carpenter, G Karpati
Pageof 22